PIK3CA and hepatocellular carcinoma: IBL-302 is a (PIM/PI3K/mTOR) inhibitor, so it maintains the potential to be therapeutically active in a cell line with high PIM 1 (like HCC-1954) and alternatively a cell line with mutant PIK3CA (BT-474) giving it a wider scope of use.